Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose-finding study of CC-90011 in relapsed or refractory solid tumors and non-Hodgkin lymphomas
jRCT2031210081Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2021
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of pulrodemstat in Nonhematologic neoplasms and non-Hodgkin lymphoma (NHL), sponsored by Bristol Myers Squibb. Primary endpoints: Dose-limiting toxicities and Maximum tolerated dose. Started Jul 2021; status: completed.
02
Drugs
pulrodemstat
03
Conditions
Nonhematologic neoplasmsnon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on jRCT2031210081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210081.